24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Medical Disorders
Resources
Basic InformationLookupsLatest News
Hot Water Soak May Help Ease Poor Leg CirculationHealth Tip: Understanding RosaceaHealth Tip: Causes of Swollen Lymph NodesAHA News: Study Provides Rare Look at Stroke Risk, Survival Among American IndiansCDC Opens Emergency Operations Center for Congo Ebola OutbreakScared Safe: Pics of Sun's Damage to Face Boost Sunscreen UseNo Needle Prick: Laser-Based Test Hunts Stray Melanoma Cells in BloodBats Are Biggest Rabies Danger, CDC SaysEmgality Receives First FDA Approval for Treating Cluster HeadacheZerbaxa Approved for Hospital-Acquired Bacterial PneumoniaBlood From Previously Pregnant Women Is Safe for Donation: StudyStudy Refutes Notion That People on Warfarin Shouldn't Eat Leafy GreensCancer Survivors Predicted to Top 22 Million by 2030Your Guide to a Healthier Home for Better Asthma ControlHigh Blood Pressure at Doctor's Office May Be More Dangerous Than SuspectedAHA News: 3 Simple Steps Could Save 94 Million Lives WorldwideHealth Tip: Dealing With Motion SicknessHealth Tip: Symptoms of MeningitisRace Affects Life Expectancy in Major U.S. CitiesVitamin D Supplements Don't Prevent Type 2 Diabetes: StudyChickenpox Vaccine Shields Kids From Shingles, TooWhooping Cough Vaccine Effectiveness Fades With Time: StudyOpioids Put Alzheimer's Patients at Risk of Pneumonia: StudyHealth Tip: Early Signs of Lyme DiseaseHealth Tip: Hiccup Home RemediesSheep Study Shows a Stuffy Side Effect of VapingShould Air Quality Checks Be Part of Your Travel Planning?Health Tip: Preventing Swimmer's EarHeartburn Drugs Again Tied to Fatal RisksHealth Tip: Nasal Spray SafetyFDA Approves First Drug to Help Tame Cluster HeadachesMany Dietary Supplements Dangerous for TeensAverage American Ingests 70,000 Bits of Microplastic Each YearFalls Are Increasingly Lethal for Older AmericansChicken No Better Than Beef for Your Cholesterol?Another Use for Beta Blockers? Curbing A-fibCaffeine, Nicotine Withdrawal Can Cause Problems in the ICU: StudyYounger Gout Patients Have Higher Odds for Blood ClotsFDA Approves First Test for Zika in Human BloodCDC Warns Again of Salmonella From Pet HedgehogsWhy Some Kids With Eczema Are at Higher Allergy RiskMany Heart Failure Patients Might Safely Reduce Use of DiureticsU.S. Measles Cases for 2019 Already Exceed All Annual Totals Since 1992: CDCForget Fasting Before That Cholesterol TestU.S. Cancer Cases, Deaths Continue to Fall'Controlled Burns' Better for Kids' Health Than Wildfires: StudyHighly Processed Diets Tied to Heart Disease, Earlier DeathHealth Tip: Signs of Irritable Bowel SyndromeA Less Invasive Fix Works Well for Abdominal AneurysmFace Transplants Improve Lives Years Later
Questions and AnswersLinks
Related Topics

Diabetes

Broad-Range Ebola Drug Shows Promise in Animal Tests

HealthDay News
by -- Robert Preidt
Updated: Jan 11th 2019

new article illustration

FRIDAY, Jan. 11, 2019 (HealthDay News) -- An experimental Ebola drug was effective against all strains of the deadly virus in laboratory animals, scientists say.

Previous research typically took the "one bug, one drug" approach, said researcher Thomas Geisbert, a professor at the University of Texas Medical Branch at Galveston. But due to the unpredictable nature of Ebola, scientists have been trying to develop protection against multiple strains of the virus, he added.

A single dose of a two-antibody drug fully protected monkeys and ferrets against the Bundibugyo and Sudan strains, as well as the deadliest Zaire strain responsible for the 2013-2016 epidemic in West Africa and the current outbreak in the Democratic Republic of Congo, the researchers said. The drug is called MBP134.

"Our experimental drug can protect against all forms of Ebola known to harm people, suggesting that it will continue to protect people if the Ebola viruses evolve over time," Geisbert said in a school news release.

"We were able to protect the nonhuman primates against all the Ebola species plaguing people at a single low dose," said Larry Zeitlin, president of drug maker Mapp Biopharmaceutical Inc. of San Diego.

Further studies using even lower doses could open the door to auto-injector treatment like the kind used for allergic reactions, Zeitlin said.

However, it's important to note that results of animal experiments aren't necessarily applicable to humans.

Still, "the ability to quickly and efficiently provide protection against all Ebola viruses in a single dose would reduce the burden on health care workers in the field during outbreaks, especially in regions that have a less-developed infrastructure," Zeitlin added.

The research was published Jan. 9 in the journal Cell Host & Microbe.

More information

The U.S. Centers for Disease Control and Prevention has more on Ebola.